Endocrine-Related Cancer

Papers
(The TQCC of Endocrine-Related Cancer is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity78
Cancer in Ecuadorian subjects with Laron syndrome (ELS)55
Radioiodine: 80 years and counting; the past, present, and future49
Association of DNA methylation with steroidogenic enzymes in Cushing’s adenoma44
Targeting growth hormone in cancer: future perspectives42
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing42
Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma35
Management of early-stage metastatic prostate cancer: appraisal of locoregional treatments and radiation therapy, with or without immunomodulation34
Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer33
TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models31
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy27
Acknowledgement to reviewers27
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas26
Celebrating the 80th anniversary of hormone ablation for prostate cancer25
Advancements and challenges in pheochromocytoma and paraganglioma research: a collection of insights24
One hundred years after the discovery of insulin and glucagon: the history of tumors and hyperplasias that hypersecrete these hormones24
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications24
Outcome and prognostic factors for pituitary carcinomas: lessons from a systematic review23
A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy22
A pilot study of the immune microenvironment of GI neuroendocrine carcinoma22
Glycoprotein non-metastatic melanoma protein B promotes tumor growth and is a biomarker for lymphangioleiomyomatosis21
Genetic disorders and insulinoma/glucagonoma20
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice20
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland20
B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors20
Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitors19
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells19
Two distinct classes of thymic tumors in patients with MEN1 show LOH at the MEN1 locus18
AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer18
Acknowledgement to reviewers18
Liquid biopsies in thyroid cancers: a systematic review and meta-analysis18
Expression and clinical significance of VISTA and PD-L1 in adrenocortical carcinoma17
Thyroid status regulates the tumor microenvironment delineating breast cancer fate17
Preclinical evaluation of targeted therapies in Sdhb-mutated tumors17
Congenital hypothyroidism and thyroid cancer17
AGEs induce MMP-9 promoter demethylation through the GADD45α-mediated BER pathway to promote breast cancer metastasis in patients with diabetes17
Exercise intensity and markers of inflammation during and after (neo-) adjuvant cancer treatment16
Pan-genomic characterization of high-risk pediatric papillary thyroid carcinoma16
Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients16
Update on the genetics of paragangliomas16
Nutrition, GH/IGF-1 signaling, and cancer16
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial16
Prognostic of recurrence and survival in poorly differentiated thyroid cancer16
The role of vitamin D in breast cancer risk and progression15
Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer15
Multivariable model versus AJCC staging system: cancer-specific survival predictions in adrenocortical carcinoma15
Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine15
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review14
Aggressive versus indolent insulinomas: new clinicopathological insights13
Global trends in thyroid cancer 1990–2021: an analysis based on the GBD 202113
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs13
Deiodinases in thyroid tumorigenesis12
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells12
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management12
Radioiodine treatment: an historical and future perspective12
Clinicopathologic features of thyroid nodules with PTEN mutations on preoperative testing12
Genomic alterations impact cell cycle-related genes during prostate cancer progression11
Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms11
Germline pathogenic variants in patients with early-onset neuroendocrine neoplasms11
Mammary carcinoma in aged gerbil mothers after endocrine disruption in pregnancy and lactation11
Molecular alterations in Hürthle cell nodules and preoperative cancer risk11
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome11
Hypoxia-associated genetic signature in ovarian steroid cell tumor NOS11
DIPNECH: pragmatic approach, uncertainties, notable associations, and a proposal for an improved definition11
Nuclear medicine in pheochromocytoma and paraganglioma: at a crossroads with precision medicine11
Talking about sex: erectile dysfunction in the oncology patient10
Non-pituitary GH regulation of the tissue microenvironment10
Clinical and basic research implications of the article ‘IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer’10
Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome10
Beyond the three P’s: adrenal involvement in MEN110
Primary tumour resection in metastasised adrenocortical carcinoma10
Detection and yield of thyroid cancer surveillance in adults with PTEN hamartoma tumour syndrome10
Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer10
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet10
Activation of the HIF1α/TIMP1/MT6-MMP pathway is associated with invasion in pituitary null cell adenomas10
The link between aberrant splicing and B cell infiltration in breast cancer hormone therapy10
Germline CDKN1B variant type and site are associated with phenotype in MEN49
PARP inhibitors in advanced prostate cancer: when to use them?9
Incident atrial fibrillation in patients with differentiated thyroid cancer: a meta-analysis9
A zebrafish xenotransplant model of anaplastic thyroid cancer to study tumor microenvironment and innate immune cell interactions in vivo9
Genome-wide crosstalk between steroid receptors in breast and prostate cancers9
Cancer clocks in tumourigenesis: the p53 pathway and beyond9
New drug delivery strategies targeting the GnRH receptor in breast and other cancers9
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer9
Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation8
Metabolic and hormonal remodeling of colorectal cancer cell signaling by diabetes8
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal8
ERRATUM: Mutational landscape of non-functional adrenocortical adenomas8
Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal8
Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures8
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort8
Prostate cancer and bone: clinical presentation and molecular mechanisms8
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts8
Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer8
ERRATUM: The role of oestrogen receptor α in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER28
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma8
Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs8
RETRACTION: Improvement of chemotherapeutic drug efficacy by endoplasmic reticulum stress8
0.069236040115356